Issue Date: April 4, 2011
Gilead, Sanofi Ink Academic R&D Pacts
Gilead Sciences and Yale School of Medicine have formed a multiyear collaboration to discover novel cancer therapies. Research will focus on the genetic basis and underlying mechanisms of cancer. Gilead will fund the initial four-year research period with up to $40 million and could pay as much as $100 million over 10 years if the project is renewed. Meanwhile, Sanofi-Aventis has formed a collaboration with Columbia University Medical Center focused on diabetes treatments. The three-year project will investigate the role of osteocalcin, an osteoblast-secreted peptide, in diabetes management. Sanofi will fund research at Columbia and will have an option to license existing patents and results from ongoing research.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society